Results 41 to 50 of about 5,052,415 (279)

Relationship between pulmonary and cardiac abnormalities in sickle cell disease: implications for the management of patients

Revista Brasileira de Hematologia e Hemoterapia, 2016
Objective: To evaluate the association between clinical, pulmonary, and cardiovascular findings in patients with sickle cell disease and, secondarily, to compare these findings between sickle cell anemia patients and those with other sickle cell diseases.
Maria Christina Paixão Maioli, Andrea Ribeiro Soares, Ricardo Bedirian, Ursula David Alves, Cirlene de Lima Marinho, Agnaldo José Lopes   +5 more
doaj   +1 more source

Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase

British Journal of Clinical Pharmacology, EarlyView.
Aim Novel oral polio vaccine type 2 (nOPV2) was used under the WHO emergency use listing for circulating vaccine‐derived polio virus (cVDPV) outbreaks from 2021 to 2023. We assessed nOPV2 adverse events following immunization (AEFIs) and compared its safety profile to other vaccines using VigiBase.
Comfort Kunak Ogar, Malede Mequanent Sisay, Leonardo Roque‐Pereira, Christine Leopold, Patrick C. Souverein, Aukje K. Mantel‐Teeuwisse, Marie L. De Bruin   +6 more
wiley   +1 more source

Coexistent sickle cell anemia and autoimmune hemolytic anemia in two adolescents [PDF]

Einstein (São Paulo)
The development of alloantibodies or autoantibodies is a complication observed in sickle cell disease. Autoimmunization occurs in 7.6-12% of chronically or intermittently transfused patients with sickle cell disease; however, the clinical implications of
Vinícius Reis Soares, Bruna Paccola Blanco, Carla Luana Dinardo, Marlene Pereira Garanito   +3 more
doaj   +1 more source

Severe Multiorgan Failure Triggered by Infection in an Adult With Decades of Untreated Sickle Cell Disease: A Case Report. [PDF]

Clin Case Rep
ABSTRACT A 67‐year‐old man with decades of untreated sickle cell disease developed septic shock with multiorgan failure, splenic infarction, and marrow fibrosis; his genotype could not be confirmed. He recovered with intensive supportive care, with hydroxyurea initiated for long‐term disease modification, illustrating catastrophic infection‐triggered ...
Shahidi S, Mohan G.
europepmc   +2 more sources

Ceftriaxone‐associated immune haemolytic anaemia: A patient‐level systematic review

British Journal of Clinical Pharmacology, EarlyView.
Abstract Ceftriaxone can cause acute haemolysis. Its clinical presentation, risk factors, and outcomes remain incompletely characterized. We conducted a systematic review of published cases with patient‐level data, following international guidelines and with registration in PROSPERO (CRD420261338709). Reports were identified through three bibliographic
Sonja Miotti, Giada Wyttenbach, Mario G. Bianchetti, Camilla Lavagno, Pietro Camozzi, Gregorio P. Milani, Renato Gualtieri, Sebastiano A. G. Lava, Pietro B. Faré, Simone Janett   +9 more
wiley   +1 more source

Hemoglobin E Disorders in South Gujarat – A Study Of 35 Cases

National Journal of Community Medicine, 2012
Background:Among the inherited disorders of blood, hemoglobinopathies and thalassemia constitute a major bulk of non-communicable genetic disease in India.
B M Jha, Bhavna Gamit, Jitendra Patel, Kunal J Prajapati   +3 more
doaj  

Clinical Model‐Informed Precision Dosing Consult Service for Accelerating Personalized Medication in Pediatric Patients

Clinical Pharmacology &Therapeutics, EarlyView.
Traditional dosing strategies often rely on a “one‐size‐fits‐all” paradigm, assuming an “average” patient with typical demographic and pharmacological characteristics. In reality, this often overlooks existing between‐patient variability and can lead to suboptimal drug exposure or toxicity. This issue is especially pronounced in pediatric patients, who
Zachary L. Taylor, Takanobu Nadai, Kei Irie, Wen Rui Tan, Sanjana Parikh, Anhar Hosawi, Matthijs W. van Hoogdalem, Ronaldo Morales Junior, Sonya Tang Girdwood, Abbie D. Leino, Kana Mizuno, Alexander A. Vinks, Tomoyuki Mizuno   +12 more
wiley   +1 more source

Model‐Informed Evaluation of Hydroxyurea Exposure During Lactation

Clinical Pharmacology &Therapeutics, EarlyView.
Hydroxyurea is a cornerstone therapy for sickle cell anemia; however, evidence guiding its use during lactation remains limited. This study aimed to develop a population pharmacokinetic (PK) model to characterize hydroxyurea disposition in maternal plasma and breast milk, and to quantify infant exposure under clinically relevant breastfeeding scenarios.
Anhar Hosawi, Kei Irie, Min Dong, Julie Ware, Russell Ware, Tomoyuki Mizuno   +5 more
wiley   +1 more source

Influence of ?S-globin haplotypes and hydroxyurea on tumor necrosis factor-alpha levels in sickle cell anemia

Revista Brasileira de Hematologia e Hemoterapia, 2014
Background: Sickle cell anemia is a chronic inflammatory disease characterized by an increased production of proinflammatory cytokines including tumor necrosis factor-alpha.
Marília Rocha Laurentino, Pedro Aurio Maia Filho, Maritza Cavalcante Barbosa, Izabel Cristina Justino Bandeira, Lilianne Brito da Silva Rocha, Romelia Pinheiro Gonçalves   +5 more
doaj   +1 more source

Sickle-cell anemia—a review

The Journal of Emergency Medicine, 1988
Sickle-cell anemia is a common disease, affecting more than 50,000 blacks in the United States. Since 1970 the morbidity and mortality have improved, with patients surviving well into their fourth decade. This article discusses the spectrum of serious complications of sickle-cell anemia.
Resident in Emergency Medicine, Division of Emergency Medicine, Department of Surgery, University Hospital of Jacksonville, Florida, USA ( host institution ), Galloway, Sherry J., Harwood-Nuss, Ann L.   +2 more
openaire   +3 more sources